Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
By Stephen J. Ubl | February 24, 2021
This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections.
Read More
ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response
By Jocelyn Ulrich | February 22, 2021
As America’s biopharmaceutical researchers continue working around the clock to fight COVID-19, leaders in the health care ecosystem have come together to provide recommendations to strengthen...
Read More
Fighting variants of COVID-19
By Richard Moscicki, M.D. | February 22, 2021
As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is working around the clock to develop and manufacture safe and effective vaccines. To date, two...
Read More
Key excerpts: PhRMA submits comments to keep the six protected classes protected
By Tom Wilbur | February 19, 2021
Earlier this month, PhRMA submitted comments to CMS regarding the Part D Payment Modernization Model Request for Applications (RFA) for calendar year 2022. This RFA was released on January 19,...
Read More
Top five issues voters want addressed in the administration’s first 100 days
By Mark Keida | February 18, 2021
When voters cast their ballots in the 2020 election, they made clear their focus on getting COVID-19 under control and fixing the economy. However, health care was still important to many voters,...
Read More
The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
By Tom Wilbur | February 12, 2021
Strong and reliable IP protections – including patents – have supported America’s robust innovation ecosystem by promoting discovery, development, affordability and access to new treatments and...
Read More
Beyond output and employment: The impact of America’s biopharmaceutical industry
By Ryan Garofalo | February 11, 2021
Particularly in recent times, biopharmaceutical companies have become increasingly important to the American economy. But just how valuable are they? In the United States, these businesses support...
Read More
Lessons learned from COVID-19: The way we develop new medicines is changing
By Richard Moscicki, M.D. | February 10, 2021
The COVID-19 pandemic has affected nearly every aspect of society, including the way scientists conduct the testing of medicines.
Read More
Action needed to preserve the six protected classes
By Tom Wilbur | February 3, 2021
In the final hours of the previous Administration’s time in office, the Center for Medicare & Medicaid Innovation (the Innovation Center) (CMMI) announced new changes for CY 2022 to an existing...
Read More
Insurers shift medicine costs to patients with severe chronic illnesses
By Gabby Migliara | February 1, 2021
For many patients with complex and chronic conditions, high out-of-pocket costs for medicines pose a significant challenge. Recent research revealed a broken insurance system that fails to help...
Read More
Tennessee’s Medicaid demonstration fails patients
By Hannah Loiacono | February 1, 2021
Prior to its departure from office, the Trump Administration approved Tennessee’s request for a demonstration to change how the state’s Medicaid program operates, and more importantly, how...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
